HK1141444A1 - Composition for transmucosal delivery of polypeptides - Google Patents

Composition for transmucosal delivery of polypeptides

Info

Publication number
HK1141444A1
HK1141444A1 HK10107847.8A HK10107847A HK1141444A1 HK 1141444 A1 HK1141444 A1 HK 1141444A1 HK 10107847 A HK10107847 A HK 10107847A HK 1141444 A1 HK1141444 A1 HK 1141444A1
Authority
HK
Hong Kong
Prior art keywords
biologically active
transmucosal
active polypeptide
polypeptides
dosage form
Prior art date
Application number
HK10107847.8A
Other languages
English (en)
Inventor
Steve L Durfee
Gary B Thurman
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of HK1141444A1 publication Critical patent/HK1141444A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
HK10107847.8A 2007-05-01 2010-08-17 Composition for transmucosal delivery of polypeptides HK1141444A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92700607P 2007-05-01 2007-05-01
PCT/US2008/005655 WO2008137054A2 (en) 2007-05-01 2008-05-01 Composition for transmucosal delivery of polypeptides

Publications (1)

Publication Number Publication Date
HK1141444A1 true HK1141444A1 (en) 2010-11-12

Family

ID=39944167

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10107847.8A HK1141444A1 (en) 2007-05-01 2010-08-17 Composition for transmucosal delivery of polypeptides

Country Status (19)

Country Link
US (2) US20100111902A1 (hr)
EP (2) EP2316472A1 (hr)
JP (1) JP5611033B2 (hr)
CN (1) CN101674843A (hr)
AT (1) ATE495753T1 (hr)
AU (1) AU2008248228B2 (hr)
CA (1) CA2685853A1 (hr)
CY (1) CY1111422T1 (hr)
DE (1) DE602008004656D1 (hr)
DK (1) DK2155229T3 (hr)
ES (1) ES2359875T3 (hr)
HK (1) HK1141444A1 (hr)
HR (1) HRP20110273T1 (hr)
IL (1) IL201563A (hr)
MX (1) MX2009011784A (hr)
NZ (1) NZ580967A (hr)
PL (1) PL2155229T3 (hr)
SI (1) SI2155229T1 (hr)
WO (1) WO2008137054A2 (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9445992B2 (en) 2009-11-25 2016-09-20 Arisgen Sa Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion
RU2519099C1 (ru) * 2012-11-08 2014-06-10 Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН) Фармацевтическая композиция
CN104667254A (zh) * 2013-11-29 2015-06-03 中国科学院兰州化学物理研究所 一种鱼低聚肽泡腾片及其制备方法
CN104840958B (zh) * 2015-05-28 2018-03-30 广州帝奇医药技术有限公司 人工粘膜组合物及其制备方法和应用
WO2019082221A2 (en) * 2017-10-23 2019-05-02 Biofarma S.P.A. DEVICE AND METHOD FOR ORAL ADMINISTRATION OF ACTIVE PRINCIPLES
IT201700120081A1 (it) * 2017-10-23 2019-04-23 Biofarma S P A Dispositivo e metodo per la somministrazione orale di principi attivi
CA3087733A1 (en) 2018-01-23 2019-08-01 Gila Therapeutics, Inc. Peptide yy pharmaceutical formulations, compositions, and methods
CA3137919A1 (en) * 2019-05-20 2020-11-26 Poviva Corp. Compositions comprising biologically active agents and bile salts
US20220249465A1 (en) * 2019-05-31 2022-08-11 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US142197A (en) * 1873-08-26 Improvement in fanning-mills
US2735304A (en) 1956-02-21 toppfb haw
US169989A (en) * 1875-11-16 Improvement in iron fences
US163838A (en) * 1875-06-01 Improvement in mariners compasses
US142198A (en) * 1873-08-26 Improvement in windmills
US2613204A (en) 1952-10-07 of urea
GB697914A (en) 1949-10-24 1953-09-30 Ruf Buchhaltung Ag Improvements in and relating to a sheet feeding and guiding device for a typewriter
BE502283A (hr) 1950-03-31
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
JP2911496B2 (ja) 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5482706A (en) 1992-04-17 1996-01-09 Takeda Chemical Industries, Ltd. Transmucosal therapeutic composition
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
PT1015352E (pt) 1997-04-01 2007-09-24 Cima Labs Inc ''embalagem alveolar e comprimidos embalados''
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
MXPA06007453A (es) 2003-12-31 2007-01-31 Cima Labs Inc Forma de dosificacion de opiaceo oral efervescente.
DE602004031462D1 (de) 2003-12-31 2011-03-31 Cima Labs Inc Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form

Also Published As

Publication number Publication date
CA2685853A1 (en) 2008-11-13
AU2008248228A1 (en) 2008-11-13
ES2359875T3 (es) 2011-05-27
IL201563A (en) 2013-05-30
AU2008248228B2 (en) 2012-10-18
DE602008004656D1 (de) 2011-03-03
JP2010526071A (ja) 2010-07-29
MX2009011784A (es) 2009-11-13
CN101674843A (zh) 2010-03-17
EP2155229A2 (en) 2010-02-24
CY1111422T1 (el) 2015-08-05
ATE495753T1 (de) 2011-02-15
US20120076757A1 (en) 2012-03-29
IL201563A0 (en) 2010-05-31
SI2155229T1 (sl) 2011-05-31
EP2316472A1 (en) 2011-05-04
PL2155229T3 (pl) 2011-06-30
EP2155229B1 (en) 2011-01-19
WO2008137054A3 (en) 2009-06-04
WO2008137054A2 (en) 2008-11-13
HRP20110273T1 (hr) 2011-05-31
US20100111902A1 (en) 2010-05-06
DK2155229T3 (da) 2011-05-09
NZ580967A (en) 2012-04-27
JP5611033B2 (ja) 2014-10-22

Similar Documents

Publication Publication Date Title
HK1141444A1 (en) Composition for transmucosal delivery of polypeptides
WO2008027854A3 (en) Pharmaceutical compositions comprising hgh for oral delivery
IL172783A0 (en) Rasgap derived peptide for selectively killing cancer cells
BRPI0418228A (pt) forma de dosagem, e, métodos de tratamento de dor e de episódios de dor incidente de cáncer, e de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
CA2549642A1 (en) Effervescent oral opiate dosage forms and methods of administering opiates
WO2005065317A3 (en) Effervescent oral fentanyl dosage form
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
WO2007061829A3 (en) Pharmaceutical composition
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
DE602008006700D1 (hr)
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
TW200611697A (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
NO20024673L (no) Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin
HK1126790A1 (en) Biologically active peptide vapeehptllteaplnpk derivatives
WO2008133952A3 (en) Transmucosal treatment with fentanyl in patients with mucositis
TW200611696A (en) Effervescent oral fentanyl dosage form and methods of administering fentanyl
UA91824C2 (ru) Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения
AR048000A1 (es) Forma de dosificacion oral efervescente substancialmente lineal de fentanilo y metodos de administracion
AR047999A1 (es) Forma de dosificacion oral efervescente de fentanilo y metodos de administracion de fentanilo
TH80954B (th) สารผสมและวิธีการสำหรับการบำบัดโรคหอบหืด

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160501